Skip to content
Screener

Travere Therapeutics, Inc. TVTX Business Segments — Total Revenue

Similar metrics at other companies

DocuSign logo
DOCUReportable Segment — Total Revenue
$830.24M+8.7%
Guidewire Software logo
GWREReportable Segment — Total Revenue
$372.54M+26.9%
UiPath logo
PATHReportable Segment — Total Revenue
$418.38M+17.3%
Andersen Group logo
ANDGReportable Segment — Total Revenue
$240.75M+15.7%
Lemonade logo
LMNDReportable Segment — Total Revenue
$258M+70.6%
Spyre Therapeutics, Inc. logo
SYREReportable Segment — Total Revenue
$0

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Revenue$127,199$81,732
Less:
Cost of goods sold1,9504,679
Research and development:
External research and development27,72822,355
Internal personnel costs24,52520,102
Other research and development4,8414,432
Total research and development57,09446,889

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s business segments — total revenue?
Travere Therapeutics, Inc. (TVTX) reported business segments — total revenue of $127.2M in Q1 2026.
How has Travere Therapeutics, Inc.'s business segments — total revenue changed year-over-year?
Travere Therapeutics, Inc.'s business segments — total revenue increased by 55.6% year-over-year, from $81.73M to $127.2M.
What is the long-term trend for Travere Therapeutics, Inc.'s business segments — total revenue?
Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — total revenue has grown at a 64.9% compound annual growth rate (CAGR), from $109.46M to $490.73M.
What does business segments — total revenue mean?
This metric represents the total gross income generated by the company's primary business segment through the sale of pharmaceutical products and therapeutic services. It serves as a key indicator of market adoption and commercial success for the company's rare disease portfolio.

Ask your AI about Travere Therapeutics, Inc.'s business segments — total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude